SHBG and polycystic ovary syndrome: After 12 weeks of treatment, the COM group had significant differences in the serum TT levels [(0.79 ± 0.31) ng/mL vs. (0.62 ± 0.24) ng/mL, P = 0.032], serum SHBG levels [22.40 (15.25–34.60) nmol/L vs. 27.00 (22.60–44.90) nmol/L, P = 0.018], and FAI [12.72 (6.40–17.71)% vs. 7.06 (3.90–10.19)%, P = 0.004] when compared with those in the MET group, indicating that MET plus LIRA therapy may be more effective than MET monotherapy in improving HA in overweight patients with PCOS.